ArticleTherapeutic advances in musculoskeletal disease2026
Precision imaging biomarkers for gout: artifact-specific spectral CT parameters for personalized differentiation of tophi in a prospective study.
Article in Therapeutic advances in musculoskeletal disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spectral computed tomography (CT) enables non-invasive visualization and quantification of monosodium urate deposits and has an important role in gout diagnosis and monitoring. However, artifact-related false-positive findings may reduce diagnostic confidence, particularly when artifacts show attenuation features overlapping with tophi. Objectives: To evaluate advanced spectral CT parameters as quantitative imaging biomarkers for differentiating tophi from common artifacts. Design: Prospective cross-sectional study. Methods: Consecutive participants with suspected foot gout were prospectively recruited from May 2023 to May 2024 and underwent foot spectral CT scans. Participants were classified into gout and non-gout groups. Regions of interest (ROIs) were delineated on index tophi in the gout group and on artifact regions in the non-gout group, including nail bed, skin, beam-hardening, vascular, and tendon artifacts. Conventional attenuation (HU Results: The final analysis included 82 tophus ROIs and 243 artifact ROIs. Tophi differed significantly from beam-hardening, vascular, and tendon artifacts across all parameters ( Conclusion: Spectral CT parameters may support artifact-specific tophus differentiation in gout. An artifact-specific parameter selection approach may help reduce false-positive interpretations and improve confidence in spectral CT-based gout assessment. Trial registration: Chinese Clinical Trial Registry, ChiCTR2300069114, https://www.chictr.org.cn/showproj.html?proj=185804.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.